| scholarly article | Q13442814 |
| P50 | author | José Sebastião dos Santos | Q62744933 |
| P2093 | author name string | Anelisa K Coutinho | |
| Alexandre A Jácome | |||
| Aline C Andrade | |||
| Enaldo M Lima | |||
| P2860 | cites work | Mutations of PIK3CA in gastric adenocarcinoma | Q21261219 |
| Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer | Q27320322 | ||
| Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 | ||
| Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer | Q27851691 | ||
| Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study | Q27853010 | ||
| Global cancer statistics, 2012 | Q27860501 | ||
| Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma | Q27860650 | ||
| Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer | Q27860681 | ||
| The biology of VEGF and its receptors | Q27860704 | ||
| The blockade of immune checkpoints in cancer immunotherapy | Q27860852 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| Oncogenic kinase signalling | Q28189493 | ||
| Comprehensive molecular characterization of gastric adenocarcinoma | Q28244985 | ||
| Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer | Q28278736 | ||
| Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer | Q29614302 | ||
| Trastuzumab--mechanism of action and use in clinical practice | Q29615810 | ||
| Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma | Q29617568 | ||
| A gain-of-function mutation of JAK2 in myeloproliferative disorders | Q29618851 | ||
| Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer | Q29619394 | ||
| Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study | Q29620647 | ||
| Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial | Q29620687 | ||
| Nivolumab in previously untreated melanoma without BRAF mutation | Q29620688 | ||
| Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial | Q29620917 | ||
| Iniparib plus chemotherapy in metastatic triple-negative breast cancer | Q33393514 | ||
| Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study | Q33416122 | ||
| Improved survival with bevacizumab in advanced cervical cancer | Q33566222 | ||
| Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection | Q33617838 | ||
| A phase 3 trial of bevacizumab in ovarian cancer | Q34030022 | ||
| A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer | Q34051972 | ||
| Detection of kinase amplifications in gastric cancer archives using fluorescence in situ hybridization. | Q34301120 | ||
| Genetic and bioinformatic analyses of the expression and function of PI3K regulatory subunit PIK3R3 in an Asian patient gastric cancer library | Q34372857 | ||
| EGFR and cancer prognosis | Q34399312 | ||
| Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group | Q34572233 | ||
| Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial | Q34616772 | ||
| Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial | Q34634936 | ||
| Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection | Q34638268 | ||
| Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia | Q34744904 | ||
| Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer | Q35113261 | ||
| Inhibition of the JAK2/STAT3 pathway reduces gastric cancer growth in vitro and in vivo | Q35164307 | ||
| MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib | Q35666332 | ||
| A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets | Q35878807 | ||
| Patterns of initial recurrence in completely resected gastric adenocarcinoma | Q35922065 | ||
| Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial | Q36892840 | ||
| Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders | Q36919975 | ||
| The ERBB3 receptor in cancer and cancer gene therapy | Q37135372 | ||
| Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis | Q37360125 | ||
| Prognostic value of epidermal growth factor receptors in gastric cancer: a survival analysis by Weibull model incorporating long-term survivors | Q37468304 | ||
| FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study | Q37594375 | ||
| Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial | Q38099726 | ||
| Prognostic role of human epidermal growth factor receptor in gastric cancer: a systematic review and meta-analysis | Q38122908 | ||
| Vascular endothelial growth factor, hypoxia-inducible factor 1 alpha and CD34 expressions in early-stage gastric tumors: relationship with pathological factors and prognostic impact on survival | Q38429007 | ||
| FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547. | Q39181047 | ||
| Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models | Q39413387 | ||
| EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number | Q40105232 | ||
| Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model | Q40182123 | ||
| PD-L1 expression analysis in gastric carcinoma tissue and blocking of tumor-associated PD-L1 signaling by two functional monoclonal antibodies | Q40185070 | ||
| Gastric carcinoma | Q40542262 | ||
| Prognostic significance of HER2 expression based on trastuzumab for gastric cancer (ToGA) criteria in gastric cancer: an updated meta-analysis | Q43479667 | ||
| Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer | Q43620764 | ||
| Incorporation of bevacizumab in the primary treatment of ovarian cancer | Q44579933 | ||
| Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 400 | Q44754243 | ||
| Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial | Q48117450 | ||
| Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. | Q51776237 | ||
| Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. | Q51779657 | ||
| Frequent monoallelic deletion of PTEN and its reciprocal associatioin with PIK3CA amplification in gastric carcinoma. | Q52549220 | ||
| Clinicopathological and prognostic significance of HER2 overexpression in gastric cancer: a meta-analysis of the literature. | Q53134672 | ||
| Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses. | Q53242132 | ||
| Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. | Q53668957 | ||
| Fibroblast growth factor receptor 2 gene amplification status and its clinicopathologic significance in gastric carcinoma. | Q54317929 | ||
| A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer. | Q54390371 | ||
| Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. | Q54578578 | ||
| The prevalence of PIK3CA mutations in gastric and colon cancer. | Q54655912 | ||
| Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. | Q55322223 | ||
| Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer | Q56807699 | ||
| Symptomatic Gastroesophageal Reflux as a Risk Factor for Esophageal Adenocarcinoma | Q58204833 | ||
| Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer | Q61868038 | ||
| Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial | Q62628533 | ||
| Recurrence following curative resection for gastric carcinoma | Q73442414 | ||
| Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the | Q74000577 | ||
| Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients | Q81353699 | ||
| Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance | Q82793374 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | personalized medicine | Q2072214 |
| P304 | page(s) | 1160-1171 | |
| P577 | publication date | 2016-01-01 | |
| P1433 | published in | World Journal of Gastroenterology | Q15708885 |
| P1476 | title | Personalized medicine in gastric cancer: Where are we and where are we going? | |
| P478 | volume | 22 |
| Q54977436 | (S)-crizotinib reduces gastric cancer growth through oxidative DNA damage and triggers pro-survival akt signal. |
| Q64936827 | CAB39L elicited an anti-Warburg effect via a LKB1-AMPK-PGC1α axis to inhibit gastric tumorigenesis. |
| Q42060519 | Comparative efficacy and safety of Chinese herbal injections combined with the FOLFOX regimen for treating gastric cancer in China: a network meta-analysis |
| Q37602508 | Decreased expression of miR-939 contributes to chemoresistance and metastasis of gastric cancer via dysregulation of SLC34A2 and Raf/MEK/ERK pathway |
| Q37673604 | Gastric Cancer Genomics: Advances and Future Directions. |
| Q38749038 | Gastric cancer management: Kinases as a target therapy |
| Q28078111 | HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists |
| Q89821434 | Identification of molecular targets for the targeted treatment of gastric cancer using dasatinib |
| Q49950482 | PCDHGA9 acts as a tumor suppressor to induce tumor cell apoptosis and autophagy and inhibit the EMT process in human gastric cancer |
| Q91806990 | PI3K/AKT/β-Catenin Signaling Regulates Vestigial-Like 1 Which Predicts Poor Prognosis and Enhances Malignant Phenotype in Gastric Cancer |
| Q52337419 | PTEN gene silencing contributes to airway remodeling and induces airway smooth muscle cell proliferation in mice with allergic asthma. |
| Q33779412 | Poor efficacy response to trastuzumab therapy in advanced gastric cancer with homogeneous HER2 positive and non-intestinal type |
| Q92525315 | Potent and specific MTH1 inhibitors targeting gastric cancer |
| Q91689376 | Precision oncology in Latin America: current situation, challenges and perspectives |
| Q91576485 | Radiomics analysis of contrast-enhanced CT predicts lymphovascular invasion and disease outcome in gastric cancer: a preliminary study |
| Q104486593 | Somatic alterations and mutational burden are potential predictive factors for metachronous development of early gastric cancer |
| Q90395894 | TRP Channels in Digestive Tract Cancers |
| Q48189935 | Validation of the 8th AJCC staging system for gastric cancer in a population-based setting |
Search more.